Salisbury Foundation Trust

FOI_5279

Internal Reference Number: FOI_5279

Date Request Received: 08/09/2019 08:19:15

Date Request Replied To: 02/10/2019 09:25:26

This response was sent via: By Email

Request Summary: Biologics and biosimilar prescribing

Request Category: Private Individuals

 
Question Number 1:
Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs regardless of diagnosis
Treatment Total
Abatacept (Orencia)
Adalimumab biosimilar [Amgevita]
Adalimumab biosimilar [Hulio]
Adalimumab [Humira]
Adalimumab biosimilar [Hyrimoz]
Adalimumab biosimilar [Imraldi]
Apremilast (Otezla)
Baricitinib (Olumiant)
Brodalumab (Kyntheum)
Certolizumab (Cimzia)
Dimethyl Fumarate (Skilarence)
Etanercept (Enbrel)
Etanercept Biosimilar (Benepali)
Etanercept Biosimilar (Erelzi)
Golimumab (Simponi)
Guselkumab (Tremfya)
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ixekizumab (Taltz)
Rituximab (Mabthera)
Rituximab Biosimilar (Rixathon)
Rituximab Biosimilar (Truxima)
Sarilumab (Kevzara)
Secukinumab (Cosentyx)
Tildrakizumab (Ilumetri)
Tocilizumab (Ro Actemra)
Tofacitinib (Xeljanz)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)
 
Answer To Question 1:
Abatacept (Orencia) 53
Adalimumab biosimilar [Amgevita] 5
Adalimumab biosimilar [Hulio] 0
Adalimumab [Humira] 250
Adalimumab biosimilar [Hyrimoz] 0
Adalimumab biosimilar [Imraldi] 293
Apremilast (Otezla) 13
Baricitinib (Olumiant) 77
Brodalumab (Kyntheum) 4
Certolizumab (Cimzia) 47
Dimethyl Fumarate (Skilarence) 5
Etanercept (Enbrel) 17
Etanercept Biosimilar (Benepali) 187
Etanercept Biosimilar (Erelzi) 0
Golimumab (Simponi) 33
Guselkumab (Tremfya) 10
Infliximab [Flixabi] 0
Infliximab [Inflectra] 142
Infliximab [Remicade] 18
Infliximab [Remsima] 0
Ixekizumab (Taltz) 13
Rituximab (Mabthera) 18
Rituximab Biosimilar (Rixathon) 0
Rituximab Biosimilar (Truxima) 158
Sarilumab (Kevzara) 3
Secukinumab (Cosentyx) 39
Tildrakizumab (Ilumetri) 0
Tocilizumab (Ro Actemra) 56
Tofacitinib (Xeljanz) 43
Ustekinumab (Stelara) 38
Vedolizumab (Entyvio) 20

(12 months to 31/8/19)
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values